← Back to Search

Virus Therapy

1500 Valacyclovir 200 Celecoxib for COVID-19 (PASC Trial)

Phase 2

Recruiting

Led By Lucinda Bateman, MD

Research Sponsored by Bateman Horne Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

PASC Trial Summary

"This trial aims to see if taking daily doses of celecoxib and valacyclovir can safely and effectively treat patients with long-lasting symptoms of COVID-19."

Who is the study for?

This trial is for individuals experiencing long-term symptoms after COVID-19. Specific eligibility details are not provided, but typically participants must meet certain health standards and not have conditions that would exclude them from safely participating.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of daily doses of two drugs, celecoxib and valacyclovir, in varying amounts to treat prolonged COVID-19 symptoms. A placebo group is included for comparison.See study design

What are the potential side effects?

Potential side effects may include gastrointestinal issues, headaches, dizziness from Valacyclovir; Celecoxib might cause stomach pain, swelling or high blood pressure. Placebos generally have no active ingredients but can lead to perceived side effects.

PASC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Fatigue assessed with the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a Instrument

PASC Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: 750 Valacyclovir 200 CelecoxibExperimental Treatment1 Intervention

Treatment will consist of two blue 375mg valacyclovir capsules, two blue placebo capsules, and one white 200 mg celecoxib capsule

Group II: 1500 Valacyclovir 200 CelecoxibExperimental Treatment1 Intervention

Treatment will consist of four blue 375mg valacyclovir capsules and one white 200 mg celecoxib capsule

Group III: Matched Color Placebo CapsulesPlacebo Group1 Intervention

Treatment will consist of four blue placebo capsules and one white placebo capsule

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bateman Horne CenterLead Sponsor

2 Previous Clinical Trials

150 Total Patients Enrolled

Lucinda Bateman, MDPrincipal InvestigatorBateman Horne Center

3 Previous Clinical Trials

198 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals above the age of 40 eligible to participate in this research study?

"Individuals aged 18 and older but under 65 are eligible for participation in this research study."

Answered by AI

Which specific individuals meet the eligibility criteria to participate in this research endeavor?

"Individuals aged between 18 and 65 years old who have contracted COVID-19 are eligible for inclusion in this trial, which aims to recruit a cohort of 60 participants."

Answered by AI

Are there any available positions for patients in this ongoing clinical trial?

"The information available on clinicaltrials.gov confirms the ongoing recruitment of participants for this medical trial. It was initially listed on 15th October 2023 and most recently revised on 15th March 2024."

Answered by AI

What is the current number of individuals who have been admitted into this clinical research study?

"Indeed, the details on clinicaltrials.gov show that this investigation is presently in search of volunteers. It was initially listed on 10/15/2023 and last revised on 3/15/2024. The trial aims to recruit a total of 60 participants from one designated site."

Answered by AI

What are the risks associated with taking 750mg of Valacyclovir and 200mg of Celecoxib concurrently?

"Based on our evaluation at Power, the safety rating for 750mg Valacyclovir and 200mg Celecoxib is rated as 2 since it corresponds to a Phase II study with some evidence of safety but lacking efficacy data."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

LUCINDA BATEMAN, MD 2023. "Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06316843.

All > Survivor Corps